Latest Product Pipeline News

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

Osteopore Limited has drawn down an additional A$500,000 from the first tranche of its redeemable convertible notes, bringing total subscriptions close to the A$5 million tranche limit. The funds will support ongoing operations and future growth initiatives.

GreenHy2 Limited has broadened its renewable energy storage portfolio by integrating graphene-based hybrid supercapacitor batteries, reporting robust FY24 growth and advancing key customer trials.

AFT Pharmaceuticals reported a 6% revenue increase to NZ$208 million in FY25, driven by strong ANZ growth and expanding international presence. The company targets NZ$300 million revenue by FY27 amid ongoing R&D and new product launches.

Nufarm Limited reported a solid half-year performance with a 3% revenue increase and a 40% jump in underlying EBIT, driven by strong crop protection sales and cost improvements. However, net debt rose 12%, reflecting investments in omega-3 production and seed technology expansion.

Nufarm Limited posted a 3% revenue increase to $1.81 billion for the half-year ending March 2025, driven by Crop Protection growth, yet profits fell sharply due to omega-3 inventory write-downs and higher costs. The company withheld its interim dividend amid ongoing operational challenges.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.

Brightstar Resources has announced significant upgrades to its gold Mineral Resource Estimates at Laverton and Menzies, enhancing confidence in near-term mining operations ahead of its 2025 Definitive Feasibility Study.

Generation Development Group (GDG) has forged a strategic alliance with BlackRock, combining local market leadership with global investment expertise to develop innovative retirement income solutions for Australian retirees.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

Resolute Mining has completed its acquisition of the Doropo and ABC Gold Projects from AngloGold Ashanti, marking a significant expansion of its asset portfolio with no material changes since the initial announcement.